Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Posted on: Thursday, 11 September 2008, 09:00 CDT
EMERYVILLE, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , today announced it will release its fiscal 2008 fourth quarter and year-end financial results on September 16, 2008.
The Company will also host a call to discuss its financial results. Details for the fiscal year-end call are as follows:
-- Date: Tuesday, September 16, 2008 -- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT -- Dial-in number: 877-874-1565 U.S. & Canada / 719-325-4822 International
The web cast can be accessed online at: http://investor.shareholder.com/ntii/events.cfm
Telephonic Replay: A playback of the conference call will be available from 1:30 pm (ET) on September 16, 2008 to midnight (ET) on September 23, 2008. Reply number: 888-203-1112 U.S. / 719-457-0820 International Pass code: 2312764
The presentation at the Merriman Curhan Ford Investor Summit will take place on Monday, September 15, 2008 at 10:15 a.m. at the Mark Hopkins InterContinental Hotel in San Francisco. Access to the presentation can be found at: http://investor.shareholder.com/ntii/events.cfm
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.
Neurobiological Technologies, Inc.
CONTACT: Matthew M. Loar, CFO of Neurobiological Technologies, Inc.,+1-510-595-6000
Web site: http://www.ntii.com/
Source: PRNewswire-FirstCall
Related Articles
- Neurobiological Technologies Announces Board Approval of Plan of Liquidation and Dissolution
- Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center
- Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
- Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
- Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
- Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
- Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
- Neurobiological Technologies, Inc. Comments on Recent Stroke Trial Developments
- Neurobiological Technologies, Inc. Announces Sale of XERECEPT(R) to Celtic Pharma Holdings LP for Up to $48 Million
- Neurobiological Technologies, Inc. And the Food And Drug Administration Agree on the Design of the Viprinex(TM) (Ancrod) Phase III Trial for Acute Ischemic Stroke
 |
 |
User Comments (0)
RSS Feeds